Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774807 | 0.86 | HRH4 (0.52) | HRH4PIK3CBVCPSMN1; SMN2APP | |
| SCHEMBL18601592 | 0.85 | KDM5A (0.48) | HRH4PIK3CBVCPSMN1; SMN2KDM5A | |
| SCHEMBL18636741 | 0.84 | HRH4 (0.80) | HRH4PIK3CBHRH3SMN1; SMN2APP | |
| SCHEMBL1775731 | 0.83 | HRH4 (0.69) | HRH4PIK3CBVCPHRH3SMN1; SMN2 | |
| SCHEMBL4392707 | 0.83 | HRH4 (0.64) | HRH4PIK3CBHRH3 | |
| SCHEMBL12605054 | 0.80 | HRH4 (1.00) | HRH4PIK3CBHRH3 | |
| SCHEMBL1775871 | 0.80 | HRH4 (0.57) | HRH4PIK3CBVCPHRH3 | |
| SCHEMBL1775492 | 0.79 | HRH4 (0.76) | HRH4PIK3CBHRH3 | |
| SCHEMBL1775493 | 0.79 | HRH4 (0.76) | HRH4PIK3CBHRH3 | |
| SCHEMBL1775312 | 0.78 | HRH4 (0.53) | HRH4HRH3APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885PIK3CB 1970/4885VCP 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.